<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11672">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954991</url>
  </required_header>
  <id_info>
    <org_study_id>MRTX-500</org_study_id>
    <nct_id>NCT02954991</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirati Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirati Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the clinical activity of nivolumab in combination with 3 separate
      investigational agents, glesatinib, sitravatinib, or mocetinostat.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glesatinib is an orally administered multi-targeted tyrosine kinase inhibitor (TKI) that
      primarily targets the Axl and Mesenchymal-Epithelial Transition (MET) receptors.
      Sitravatinib is an orally-available, potent small molecule inhibitor or a closely related
      spectrum of receptor tyrosine kinases (RTKs) including MET, Axl, MERTK, VEGFR family, PDGFR
      family, KIT, FLT3, Trk family, RET, DDR2 and selected Eph family members. Mocetinostat is an
      orally administered histone deacetylase (HDAC) inhibitor. Nivolumab is a human IgG
      monoclonal antibody that binds to the programmed cell death-1(PD-1) receptor and blocks its
      interaction with programmed cell death ligand-1 (PD-L1) and PD-L2, releasing PD-1
      pathway-mediated inhibition of the immune response including anti-tumor immune response.
      Combining an immunotherapeutic PD-L1 checkpoint inhibitor with an agent that has both immune
      modulatory and antitumor properties could enhance the antitumor efficacy observed with
      either agent alone.

      The study will being with a lead-in dose escalation evaluation of two dose levels of each
      investigational agent in combination with nivolumab. Following completion of the lead-in
      dose escalation, enrollment into the Phase 2 study will proceed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients experiencing tumor size reduction</measure>
    <time_frame>Up to 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients experiencing adverse events</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood plasma concentration of the investigational agent</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">209</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Glesatinib and Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glesatinib oral tablet administered twice daily in combination with Nivolumab administered as 240 mg IV every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitravatinib and Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitravatinib oral capsule administered daily in combination with nivolumab administered as 240 mg IV every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mocetinostat and Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mocetinostat oral capsule administered three times weekly in combination with nivolumab administered as 240 mg IV every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glesatinib</intervention_name>
    <description>Glesatinib is a small molecule multi-targeted receptor tyrosine kinase inhibitor</description>
    <arm_group_label>Glesatinib and Nivolumab</arm_group_label>
    <other_name>MGCD265</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitravatinib</intervention_name>
    <description>Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.</description>
    <arm_group_label>Sitravatinib and Nivolumab</arm_group_label>
    <other_name>MGCD516</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mocetinostat</intervention_name>
    <description>Mocetinostat is an HDAC inhibitor.</description>
    <arm_group_label>Mocetinostat and Nivolumab</arm_group_label>
    <other_name>MGCD01013</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>nivolumab is a programmed death receptor-1 (PD-1) blocking antibody</description>
    <arm_group_label>Glesatinib and Nivolumab</arm_group_label>
    <arm_group_label>Sitravatinib and Nivolumab</arm_group_label>
    <arm_group_label>Mocetinostat and Nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of non-small cell lung cancer.

          -  Prior treatment with platinum based doublet and checkpoint inhibitor

          -  Adequate bone marrow and organ function

        Exclusion Criteria:

          -  Uncontrolled tumor in the brain

          -  Unacceptable toxicity with prior checkpoint inhibitor

          -  Impaired heart function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mirati Therapeutics Study Locator Services</last_name>
    <phone>1-844-356-0895 (toll free)</phone>
    <email>miratistudylocator@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuzhat Siddiqui</last_name>
      <phone>205-975-2618</phone>
      <email>nuzhat@uab.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nisha Parikh</last_name>
      <phone>858-822-3171</phone>
      <email>nrparikh@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospial</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Rybkin, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialist</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Connect</last_name>
      <phone>608-262-5223</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>November 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Mocetinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
